
The FDA has approved Actelion’s oral endothelin receptor antagonist Opsumit as a treatment for pulmonary arterial hypertension (PAH), a potentially …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

